BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Efficacy at lower doses than in CML is supported by in vitro data, indicating that the IC50 (drug concentration required to inhibit proliferation by 50%) for imatinib of PDGFRα-FIP1L1 is approximately 2-log lower than for BCR-ABL.